Literature DB >> 2892659

Astemizole: a long-acting, nonsedating antihistamine.

P M Krstenansky1, R J Cluxton.   

Abstract

Astemizole is a long-acting, highly selective histamine1-receptor antagonist with minimal central and anticholinergic effects. Comparison studies have shown astemizole to be equal or superior to currently available antihistamines, beclomethasone nasal spray, and cromolyn sodium in relieving allergic symptoms of seasonal and perennial allergic rhinitis. Other uses include treatment of allergic conjunctivitis and chronic urticaria. Astemizole is not as effective for treatment of acute allergic symptoms because of its delayed onset of action. Astemizole and its active metabolite, desmethylastemizole, have long elimination half-lives permitting once-daily dosing. The incidence of sedation is lower than with conventional antihistamines, but increased appetite and weight gain do occur. Astemizole should be useful for both maintenance and prophylactic therapy in patients with chronic allergic conditions who cannot tolerate the sedative or anticholinergic effects of conventional antihistamines.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2892659     DOI: 10.1177/106002808702101202

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  3 in total

1.  Spectrophotometric quantification of astemizole and its demethylated metabolite in urine after TLC separation.

Authors:  O A al-Deeb; E M Abdel-Moety; S M Bayomi; N A Khattab
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Oct-Dec       Impact factor: 2.441

Review 2.  The influence of food on the absorption and metabolism of drugs: an update.

Authors:  L Williams; D P Hill; J A Davis; D T Lowenthal
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Jul-Sep       Impact factor: 2.441

Review 3.  Grapefruit juice-drug interactions.

Authors:  D G Bailey; J Malcolm; O Arnold; J D Spence
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.